HDFC Mutual Fund has reported a decrease in its aggregate holding in Piramal Pharma Limited. As of October 28, 2026, the fund’s stake has reduced by 2.027%, bringing its total shareholding to 4.988% of the company’s paid-up equity share capital. This change follows an earlier disclosure on July 16, 2026, where the holding was 7.015%.
HDFC Mutual Fund Adjusts Piramal Pharma Holding
HDFC Mutual Fund has formally notified Piramal Pharma Limited of a reduction in its shareholding. This disclosure, made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, details a change in the aggregate holding of the HDFC Mutual Fund schemes in Piramal Pharma Limited.
Key Shareholding Changes
Previously, on July 16, 2026, HDFC Mutual Fund’s aggregate holding in Piramal Pharma Limited stood at 7.015% of the company’s paid-up equity share capital. The paid-up equity share capital was stated as Rs. 13,31,34,81,300/-, comprising 1,33,13,48,130 equity shares of Rs. 10/- each.
In a subsequent update, HDFC Mutual Fund has announced a decrease in this shareholding by 2.027% as of October 28, 2026. Consequently, the aggregate holding of the Schemes of HDFC Mutual Fund in Piramal Pharma Limited now stands at 4.988% of the company’s paid-up equity share capital. The paid-up equity share capital remains unchanged at Rs. 13,31,34,81,300/-, with 1,33,13,48,130 equity shares of Rs. 10/- each.
Disclosure Details
The detailed breakdown of the acquisition and sale, including the number of shares and their percentage relative to total and diluted share capital, is provided in Annexure 1. The mode of acquisition/sale was identified as Open Market, with the date of the transaction or intimation of allotment being October 28, 2026. The equity share capital and total voting capital of Piramal Pharma Limited before and after the said acquisition/sale remained consistent.
Source: BSE
